CAR - T Cell therapy, CAR T-Cell, Chimeric Agent Receptor, Korea, Seoul, South Korea
Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy
May 2023: Chimeric antigen receptor (CAR) T-cell therapy is an innovative development in the field of individualized cancer therapy. The patient's own T-cells are genetically modified during the manufacturing process to express a..
CAR - T Cell therapy, Seoul, South Korea
AMC opens up CAR T-Cell therapy center in Seoul
Jan 2023: The Asan Medical Center (AMC) opened the first CAR-T cell treatment facility in the country after the government approved health insurance benefits for Kymriah's CAR-T cell therapy.AMC announced on Tuesday that its canc..
ACT Therapeutics, Brian Ho-sung Min, GenScript ProBio, Seogkyoung-Kong, Seoul, South Korea
A memorandum of understanding (MOU) has been signed by GenScript ProBio to form a strategic partnership with ACT Therapeutics to develop new CAR-T cell therapies
July 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting so..
CAR T Cell therapy in Korea, Seoul, South Korea
Korean homegrown CAR T-Cell therapy is on the way
Nov 2021: The first clinical trial of South Korea's homegrown next-generation chimeric antigen receptor T (CAR-T) cell therapy, which is designed to circumvent immune checkpoint signals, has recently gotten under way.The Korea Ad..